November 26, 2024

New Member: Welcome in our cluster to Cell Signaling Technology Europe B.V.

New Member: Welcome in our cluster to Cell Signaling Technology Europe B.V.
Go back

Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community.

CST empowers scientists worldwide with innovative, high-quality tools to advance discovery. Beyond science, CST prioritizes responsibility by partnering with communities and minimizing environmental impact. As the first life science member of 1% for the Planet, CST is committed to achieving net-zero emissions by 2029. Dedicated to good science and doing good, CST drives solutions for global challenges with care and integrity.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
Vaccine Against Brain Tumors Shows Promising Long-Term Results

Vaccine Against Brain Tumors Shows Promising Long-Term Results

A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center (DKFZ), Mannheim University Medical Center, Heidelberg University Hospital, and numerous partner institutions* have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic […]

read more
VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

The next-generation platform integrates VectorBuilder’s regulatory-compliant gene delivery technology with MaxCyte’s clinically validated electroporation platform to enable robust, scalable, and reliable clinical-grade cell engineering. Chicago, IL & Rockville, MD – June 23, 2026 – VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing enabling platform technologies to […]

read more
LEEI-Platform eFIT is Available to Industry and Research

LEEI-Platform eFIT is Available to Industry and Research

KyooBe Tech is making its innovative vaccine development platform available to industry and research partners:Enabling faster and scalable vaccine production using Low-Energy Electron Irradiation (LEEI). Flexible Vaccine Manufacturing for Emerging Infectious Diseases Recent infectious disease events—from hantavirus outbreaks and meningitis cases to recurring disease outbreaks in livestock farming—highlight the need for flexibly scalable vaccine manufacturing […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp